8,324 Shares in AstraZeneca PLC $AZNCF Acquired by Diversified Trust Co

Diversified Trust Co bought a new position in shares of AstraZeneca PLC (OTCMKTS:AZNCF) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 8,324 shares of the company’s stock, valued at approximately $1,642,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Hughes Financial Services LLC purchased a new stake in shares of AstraZeneca in the fourth quarter worth approximately $34,000. Fairscale Capital LLC purchased a new position in AstraZeneca during the 4th quarter worth $37,000. Aventus Investment Advisors Inc. purchased a new position in AstraZeneca during the 1st quarter worth $46,000. Mascoma Wealth Management LLC purchased a new position in AstraZeneca during the 4th quarter worth $46,000. Finally, Resources Management Corp CT ADV bought a new stake in shares of AstraZeneca in the 4th quarter worth $61,000. Institutional investors and hedge funds own 40.87% of the company’s stock.

AstraZeneca Stock Performance

Shares of AZNCF stock opened at $187.10 on Tuesday. The firm has a 50-day moving average of $187.10 and a 200-day moving average of $186.10. AstraZeneca PLC has a one year low of $122.26 and a one year high of $195.00.

About AstraZeneca

AstraZeneca (OTCMKTS:AZNCF) is a global biopharmaceutical company that focuses on the discovery, development, manufacturing and commercialization of prescription medicines. The company’s research and development efforts are concentrated in three main therapeutic areas: oncology; cardiovascular, renal and metabolism; and respiratory, inflammation and autoimmunity. AstraZeneca’s product portfolio includes targeted therapies for lung and breast cancers, novel agents for heart failure and chronic kidney disease, and inhaled treatments for asthma and chronic obstructive pulmonary disease.

The company was formed in 1999 through the merger of Sweden’s Astra AB and the United Kingdom’s Zeneca Group, creating one of the world’s largest pharmaceutical firms.